AMGN — Amgen Inc.

Amgen Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Increased 12% year-over-year to $9.6 billion.
• Volume Growth: Up 14%, with 16 products achieving double-digit growth.
• Operating Margin: Non-GAAP operating margin at 47%.
• Free Cash Flow: Generated $4.2 billion in Q3.
• R&D Expenses: Non-GAAP R&D expenses grew 31% year-over-year, reflecting increased investment in late-stage pipeline.
• Debt Management: Retired $4.5 billion in 2024 and $6.0 billion in 2025, returning to pre-Horizon capital structure.
• Dividend: Increased dividend payment to $2.38 per share, a 6% increase from Q3 2024.

2. Strategic Updates and Business Highlights

• Product Performance: Strong growth in key products:
  • Repatha: Sales of $794 million, up 40% year-over-year.
  • EVENITY: Sales of $541 million, up 36% year-over-year.
  • TEZSPIRE: Sales of $377 million, up 40% year-to-date.
  • Biosimilars: Revenues up 52% year-over-year, now annualizing at $3 billion.
• Pipeline Progress: Advancements in late-stage programs, including MariTide and Olpasiran, with multiple Phase III studies underway.
• Access Initiatives: Launched AmgenNow, a direct-to-patient platform for Repatha, significantly lowering patient costs.

3. Forward Guidance and Outlook

• 2025 Revenue Guidance: Raised to a range of $35.8 billion to $36.6 billion.
• Non-GAAP EPS Guidance: Expected between $20.60 and $21.40.
• R&D Expense Growth: Anticipated to grow at a mid-20s percentage rate in 2025.
• Capital Expenditures: Expected to be approximately $2.2 billion to $2.3 billion for expanding manufacturing capacity.

4. Bad News, Challenges, or Points of Concern

• Generic Competition: RAVICTI faced competition from a newly launched generic, impacting future sales.
• Prolia Sales Risks: Anticipated increased competition may negatively affect Prolia sales.
• Olpasiran Study Event Rate: Lower than expected event rates in the OCEAN(a) study could delay readouts and impact confidence.
• Discontinued Trials: The FORTITUDE-102 study was stopped due to inadequate efficacy, raising concerns about the pipeline's robustness in oncology.

5. Notable Q&A Insights

• Olpasiran Confidence: Despite concerns about event rates, management remains confident in Olpasiran's potential based on strong genetic and epidemiological data.
• Biosimilar Market Dynamics: Discussion on the need for policy changes to enhance biosimilar uptake, particularly in the context of competitive pressures from established brands like Humira.
• MariTide Study Clarifications: Management clarified that the upcoming data from the MariTide Phase II trial will focus on maintenance strategies rather than direct weight loss comparisons.
• UPLIZNA Market Potential: Strong early performance in IgG4-related disease, with significant growth opportunities anticipated in generalized myasthenia gravis, despite a competitive landscape.

This summary encapsulates the key aspects of Amgen's Q3 2025 earnings call, highlighting both the positive momentum and the challenges faced by the company.